Inflammation and diabetic nephropathy

Current Diabetes Reports

Volumn 6, Issue 6, 2006, Pages 463-468

  Mora, Carmen ^b   Navarro, Juan F ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PRAVASTATIN; SALICYLIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG TARGETING; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; KIDNEY FAILURE; KIDNEY HYPERTROPHY; METABOLIC DISORDER; NONHUMAN; PATHOGENESIS; PERIPHERAL ISCHEMIA; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; RISK FACTOR;

ANIMALS; CELL ADHESION MOLECULES; CHEMOKINES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION;

EID: 33845405589     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-006-0080-1     Document Type: Review

References (78)

1. Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999, 34:795-808.
2. Pickup J, Crook M: Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998, 41:1241-1248.
3. Festa A, D'Agostino R, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 101:42-47.
4. Ford ES: Body mass index, diabetes, and C-reactive protein among US adults. Diabetes 1999, 22:1971-1977.
5. Müller S, Martin S, Koenig W, et al.: Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002, 45:805-812.
6. Temelkova-Kurktschiev T, Henkel E, Koelher C, et al.: Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 2002, 45:151.
7. Navarro JF, Mora C, Macía M, García J: Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis 2003, 42:53-61.
8. Pickup JC, Chusney GC, Thomas SM, Burt D: Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000, 67:291-300.
9. Schmidt MI, Duncan BB, Sharrett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353:1649-1652.
10. Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
11. Festa A, D'Agostino R, Tracey RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002, 51:1131-1137.
12. Spranger J, Kroke A, Möhlig M, et al.: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam study. Diabetes 2003, 52:812-817.
13. Yuan M, Konstantopoulos N, Lee J, et al.: Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
14. Freeman DJ, Norrie J, Naveed S, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
15. McFarlane SI, Muniyappa R, Francisco R, Stowers JR: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002, 87: 1451-1458.
16. Ricote M, Li AC, Wilson TM, et al.: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
17. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-85.
18. Anderson DC Jr: Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother 2005, 39:102-109.
19. Crook M: Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 2004, 21:203-207.
20. Maffei M, Fei H, Lee GH, et al.: Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci U S A 1995, 92:6957-6960.
21. Day CP, Grove J, Daly AK, et al.: Tumor necrosis factor alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia 1998, 41:430-434.
22. Fernández-Real J, Vendrell J, Ricart W, et al.: Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 2000, 49:517-520.
23. Utimura R, Fujihara CK, Mattar AL, et al.: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003, 63:209-216.
24. Wu YG, Lin H, Qi XM, et al.: Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int Immunopharmacol 2006, 6:445-453.
25. Yozai K, Shikata K, Sasaki M, et al.: Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol 2005, 16:3326-3338.
26. Tone A, Shikata K, Sasaki M, et al.: Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia 2005, 48:2402-2411.
27. Chow F, Ozols E, Nikolic-Paterson DJ, et al.: Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004, 65:116-128.
28. Gu L, Tseng SC, Rollins BJ: Monocyte chemoattractant protein-1. Chem Immunol 1999, 72:7-29.
29. Chow F, Nikolic-Paterson DJ, Ozols E, et al.: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006, 69:73-80.
30. Tashiro K, Koyanagi I, Saitoh A, et al.: Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 2002, 16:1-4.
31. Chiarelli F, Cipollone F, Mohn A, et al.: Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 2002, 25:1829-1834.
32. Morii T, Fujita H, Narita T, et al.: Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetic Complications 2003, 17:11-15.
33. Takebayashi K, Matsumoto S, Aso Y, Inukai T: Association between circulating monocyte chemoattractant protein-1and urinary albumin excretion in nonobese type 2 diabetic patients. J Diabetes Complications 2006, 20:98-104.
34. Schjoedt KJ, Rossing K, Juhl TR, et al.: Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005, 68:2829-2836.
35. Rossing K, Schjoedt KJ, Smidt UM, et al.: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care 2005, 28:2106-2112.
36. Fujisawa G, Okada K, Muto S, et al.: Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004, 66:1493-1502.
37. Han SY, Kim CH, Kim HS, et al.: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006, 17:1362-1372.
38. Takebayashi K, Matsumoto S, Aso Y, Inukai T: Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrin Metab 2006, 91:2214-2217.
39. Stauton DE, Marlin SD, Stratowa D, et al.: Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 1988, 52:925-933.
40. Matsui H, Suzuki M, Tsukuda R, et al.: Expression of ICAM-1 on glomeruli is associated with progression of diabetic nephropathy in a genetically obese diabetic rat, Wistar fatty. Diabetes Res Clin Pract 1996, 32:1-9.
41. Coimbra TM, Janssen U, Grone HJ, et al.: Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000, 57:167-182.
42. Okada S, Shikata K, Matsuda M, et al.: Intercellular adhesion molecule-1 deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003, 52:2586-2593.
43. Chow FY, Nikolic-Paterson DJ, Ozols E, et al.: Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005, 16:1711-1722.
44. Clausen P, Jacobsen P, Rossing K, et al.: Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with type1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet Med 2000, 17:644-649.
45. Guler S, Cakir B, Demirbas B, et al.: Plasma soluble intercellular adhesion molecule 1 levels are increased in type 2 diabetic patients with nephropathy. Horm Res 2002, 58:67-70.
46. Ulbrich H, Eriksson EE, Lindbom L: Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 2003, 24:640-647.
47. Anderson ME, Siahaan TJ: Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 2003, 24:487-501.
48. Hasegawa G, Nakano K, Sawada M, et al.: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 1991, 40:1007-1012.
49. Hasegawa G, Nakano K, Kondo M: Role of TNF and IL-1 in the development of diabetic nephropathy. Nefrologia 1995, 15:1-4.
50. Nakamura T, Fukui M, Ebihara I, et al.: mRNA expression of growth factors in glomeruli of diabetic rats. Diabetes 1993, 42:450-456.
51. Sugimoto H, Shikata K, Wads J, et al.: Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999, 42:878-886.
52. Royall JA, Berkow RL, Beckman JS, et al.: Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 1989, 257:L339-L410.
53. Pfeilschfer J, Pignat W, Vosbeck K, Märki F: Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. Biochem Biophys Res Commun 1989, 159:385-394.
54. Dalla Vestra M, Mussap M, Gallina P, et al.: Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005, 16:S78-S82.
55. Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspect of interleukin 6. Immunol Today 1990, 11:443-449.
56. Moriwaki Y, Yamamoto T, Shibutani Y, et al.: Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 2003, 52:605-608.
57. Nakamura A, Shikata K, Hiramatsu M, et al.: Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005, 28:2890-2895.
58. Navarro J, Milena F, Mora C, et al.: Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int 2005, 68(suppl 99):S98-S102.
59. Baud L, Ardaillou R: Tumor necrosis factor in renal injury. Miner Electrolyte Metab 1995, 21:336-341.
60. Baud L, Pérez J, Friedlander G, Ardaillou R: Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells. FEBS Lett 1998, 239:50-54.
61. Bertani T, Abbate M, Zoja C, et al.: Tumor necrosis factor induces glomerular damage in rabbit. Am J Pathol 1989, 134:419-430.
62. McCarthy E, Sharma R, Sharma M, et al.: TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 1998, 9:433-438.
63. Kalantarinia K, Awas AS, Siragy HM: Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int 2003, 64:1208-1213.
64. Ishikura H, Takahashi C, Kanagawa K, et al.: Cytokine regulation of ICAM-1 expression on human renal tubular epithelial cells in vitro. Transplantation 1991, 51:1272-1275.
65. Dipetrillo K, Coutermarsh B, Gesek FA: Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 2003, 284:F113-F121.
66. Navarro JF, Mora C, Rivero A, et al.: Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 1999, 33:458-463.
67. Han J, Thompson P, Beutler D: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990, 172:391-394.
68. Doherty GM, Jensen JC, Alexander HR, et al.: Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991, 110:192-198.
69. Segal R, Dayan M, Zinger H, Mozes E: Suppression of experimental systemic lupus erythematous (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxifylline. Lupus 2001, 10:23-31.
70. Chen YM, Ng YY, Lin SL, et al.: Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 2004, 19:1106-1115.
71. Chen YM, Chien CT, Hu-Tsai MI, et al.: Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 1999, 56:932-943.
72. Lin SL, Chen YM, Chien CT, et al.: Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 2002, 13:2916-2929.
73. DiPetrillo K, Gesek FA: Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 2004, 24:352-359.
74. Guerrero-Romero F, Rodríguez-Morán M, Paniagua-Sierra J, et al.: Pentoxifylline reduces proteinuria in insulin-dependent and non-dependent diabetic patients. Clin Nephrol 1995, 43:116-121.
75. Navarro J, Mora C, Muros M, et al.: Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomised study. Am J Kidney Dis 2003, 42:264-270.
76. Harmankaya O, Seber S, Yilmaz M: Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 2003, 25:465-470.
77. Navarro JF, Mora C, Muros M, García J: Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomised, controlled trial. J Am Soc Nephrol 2005, 16:2119-2126.
78. Chen YM, Lin SL, Chiang WC, et al.: Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int 2006, 69:1410-1415.